Bristol-Myers Squibb Company (BMY)

In the past six months (April 2025 - October 2025), Bristol Myers Squibb's stock price has experienced a decline. As of October 24, 2025, the share price was $43.83, down from $52.64 on October 28, 2024, representing a 16.74% decrease over that period. The stock was down 2.40% over the 30 days prior to October 23, 2025, and down 17.39% over the past 12 months. Shares have fallen approximately 30% from their year-high peak in March 2025 of $63.33. Key events impacting the stock include patent expirations and pipeline concerns, Phase 3 trial failures, acquisitions of Mirati Therapeutics, Karuna Therapeutics and RayzeBio, an upcoming earnings report on October 30, 2025, and a stock buyback program.

Demand for Bristol Myers Squibb's pharmaceutical products is generally stable throughout the year due to the ongoing treatment requirements for the diseases and conditions that the company's products address. The available information does not indicate pronounced demand seasonality for Bristol Myers Squibb's overall product and service portfolio.

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, licensing, manufacturing, marketing, distributing, and selling innovative medicines. The company operates within the Pharmaceuticals sector and the broader Healthcare industry, advancing therapies in oncology, hematology, immunology, cardiovascular disease, and neuroscience, utilizing both small molecules and biologics. Major products include Apixaban (Eliquis), used for atrial fibrillation; Nivolumab (Opdivo), an immuno-oncology drug; Lenalidomide (Revlimid), used to treat multiple myeloma; Abatacept (Orencia), used for autoimmune diseases; Pomalidomide (Pomalyst/Imnovid), an anti-cancer medication; Ipilimumab (Yervoy), used to treat cancer; and Luspatercept (Reblozyl), for anemia in beta thalassemia and myelodysplastic syndromes. Other notable brands include Krazati, Sprycel, and Sotyktu.

Bristol Myers Squibb is headquartered in Princeton, New Jersey, with its corporate headquarters in Lawrenceville, New Jersey, and serves a worldwide area. In 2024, 71% of the company's revenues were generated from the United States. Bristol Myers Squibb operates manufacturing units in the U.S., Switzerland, Puerto Rico, Ireland, and the Netherlands. The company is also focused on expanding the geographic footprint of its cell therapy.

Bristol Myers Squibb's brand reputation has been influenced by positive clinical trial results, including the Phase 1 Breakfree-1 study of its CD19-targeted NEX-T CAR T cell therapy and Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial confirming the efficacy and safety of Sotyktu. Promising results from a global Phase I trial for iza-bren also contributed positively. Strategic collaborations with insitro and BioNTech, as well as a milestone payment from SystImmune, have further enhanced the company's reputation. Regulatory approvals, such as the FDA's Fast Track Designation for BMS-986446 and streamlined patient monitoring requirements for cell therapy labels, have also positively impacted the brand.

Bristol Myers Squibb Company has significant institutional ownership, with 3,474 institutional owners and shareholders holding a total of 1,951,737,186 shares, representing approximately 80.78% of the shares outstanding. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., JPMorgan Chase & Co., State Street Corp., Charles Schwab Investment Management Inc., Capital International Investors and Geode Capital Management, Llc. Individual investors and public companies also hold a substantial portion of the stock, with approximately 51.38% owned by public companies and individual investors. Insider ownership is relatively low, at approximately 0.05% or 0.32%.